Temozolomide for treatment-resistant recurrent meningioma
Temozolomide for treatment-resistant recurrent meningioma
复制标题
DOI：
10.1212/01.wnl.0000118300.82017.f4
复制
发表时间：
2004-04-13
期刊：
影响因子：
9.9
通讯作者：
Groshen, S
中科院分区：
文献类型：
--
作者：
Chamberlain, MC;Tsao-Wei, DD;Groshen, S
在16例难治性脑膜瘤患者中进行了替莫唑胺（TMZ）的前瞻性II期研究。所有患者既往均接受过手术和受累野放疗;然而，无患者既往接受过化疗。TMZ口服给药，每10周连续42天。3级或以上TMZ相关毒性包括贫血（25%）、疲乏（18.7%）、中性粒细胞减少（37.5%）、癫痫发作（6.3%）和血小板减少（18.7%）。没有患者表现出神经放射学完全或部分反应。至肿瘤进展的时间范围为2.5至5.0个月（中位5.0个月）;生存期范围为4至9个月（中位7.5个月）。
A prospective Phase II study of temozolomide (TMZ) was conducted in 16 patients with refractory meningioma. All patients had previously been treated with surgery and involved-field radiotherapy; however, no patient had prior chemotherapy. TMZ was administered orally for 42 consecutive days every 10 weeks. Grade 3 or greater TMZ-related toxicity included anemia (25%), fatigue (18.7%), neutropenia (37.5%), seizures (6.3%), and thrombocytopenia (18.7%). No patient demonstrated a neuroradiographic complete or partial response. Time to tumor progression ranged from 2.5 to 5.0 months (median 5.0 months); survival ranged from 4 to 9 months (median 7.5 months).